Výsledky vyhledávání

Akademický článek

Bimekizumab efficacy and safety in Korean patients with moderate to severe plaque psoriasis: A phase 3, randomized, placebo-controlled, double-blinded study.

Autor: Youn SW; Department of Dermatology, Seoul National University Bundang Hospital, Seongnam, Korea., Jo SJ; Department of Dermatology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea., Park CJ; Department of Dermatology, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Korea., Kim DH; Department of Dermatology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea., Shin BS; Department of Dermatology, Chosun University Hospital, Gwangju, Korea., Jeong KH; Department of Dermatology, Kyung Hee University College of Medicine, Seoul, Korea., Bang CH; Department of Dermatology, Seoul St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea., Cross N; UCB Pharma, Morrisville, North Carolina, USA., Thirlwell J; Allegis Group, Bracknell, UK.; UCB Pharma, Slough, UK., Hoepken B; UCB Pharma, Monheim, Germany.

Publikováno v: The Journal of dermatology [J Dermatol] 2024 Nov; Vol. 51 (11), pp. 1392-1403. Date of Electronic Publication: 2024 Sep 27.

Zobrazit plný text záznamu

Akademický článek

Performance analysis of a deep-learning algorithm to detect the presence of inflammation in MRI of sacroiliac joints in patients with axial spondyloarthritis.

Autor: Nicolaes J; Department of Electrical Engineering (ESAT), Center for Processing Speech and Images, KU Leuven, Leuven, Belgium joeri.nicolaes@ucb.com.; UCB Pharma, Brussels, Belgium., Tselenti E; UCB Pharma, Slough, UK., Aouad T; Universite Paris-Saclay, CentraleSupelec, Inria, Gif-sur-Yvette, France., López-Medina C; Rheumatology Department, Reina Sofia Hospital, Cordoba / IMIBIC / University of Cordoba, Cordoba, Spain., Feydy A; Radiology B Department, AHPH Cochin Hospital, Université Paris Cité, Paris, France., Talbot H; Universite Paris-Saclay, CentraleSupelec, Inria, Gif-sur-Yvette, France., Hoepken B; UCB Pharma, Monheim am Rhein, Germany., de Peyrecave N; UCB Pharma, Brussels, Belgium., Dougados M; Rheumatology Department, Cochin Hospital, Paris, France.; INSERM (U1153): Clinical Epidemiology and Biostatistics, University of Paris, Paris, France.

Publikováno v: Annals of the rheumatic diseases [Ann Rheum Dis] 2024 Oct 02. Date of Electronic Publication: 2024 Oct 02.

Zobrazit plný text záznamu

Akademický článek

Comparison of established and preliminarily proposed ASAS MRI working group cut-offs for inflammatory MRI lesions in the sacroiliac joints in radiographic and non-radiographic axial spondyloarthritis.

Autor: Baraliakos X; Rheumazentrum Ruhrgebiet, Ruhr University Bochum, Herne, Germany baraliakos@me.com., Machado PM; Department of Rheumatology, University College London Hospitals NHS Foundation Trust, London, UK.; Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, London, UK.; Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK., Bauer L; UCB Pharma, Monheim am Rhein, Germany., Hoepken B; UCB Pharma, Monheim am Rhein, Germany., Kim M; UCB Pharma, Smyrna, Georgia, USA., Kumke T; UCB Pharma, Monheim am Rhein, Germany., Tham R; UCB Pharma, Slough, UK., Rudwaleit M; Klinikum Bielefled, University of Bielefeld, Bielefeld, Germany.

Publikováno v: RMD open [RMD Open] 2024 Sep 03; Vol. 10 (3). Date of Electronic Publication: 2024 Sep 03.

Zobrazit plný text záznamu

Akademický článek

Long-term clinical outcomes of certolizumab pegol treatment in non-radiographic axial spondyloarthritis stratified by baseline MRI and CRP status.

Autor: Rudwaleit M; Klinikum Bielefeld, University of Bielefeld, Bielefeld, Germany MARTIN.RUDWALEIT@KLINIKUMBIELEFELD.DE., Deodhar A; Oregon Health & Science University, Portland, Oregon, USA., Bauer L; UCB Pharma, Monheim am Rhein, Germany., Gensler L; University of California, San Francisco, California, USA., Hoepken B; UCB Pharma, Monheim am Rhein, Germany., Kumke T; UCB Pharma, Monheim am Rhein, Germany., Auteri SE; UCB Pharma, Milan, Italy., Kim M; UCB Pharma, Smyrna, Georgia, USA., Maksymowych W; Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.

Publikováno v: RMD open [RMD Open] 2024 May 09; Vol. 10 (2). Date of Electronic Publication: 2024 May 09.

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

LONG-TERM CLINICAL OUTCOMES OF CERTOLIZUMAB PEGOL TREATMENT IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS STRATIFIED BY BASELINE MRI AND C-REACTIVE PROTEIN STATUS

Autor: Robinson, P., Maksymowych, W. P., Gensler, L. S., Rudwaleit, Martin, Hoepken, B., Bauer, L., Kumke, T., Kim, M., Deodhar, A.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2294::68962d604b7f93aa8d74d5b90a8adca5
https://doi.org/10.1136/annrheumdis-2022-eular.2834

Zobrazit plný text záznamu

Akademický článek

Achievement of higher thresholds of clinical responses and lower levels of disease activity is associated with improvements in workplace and household productivity in patients with axial spondyloarthritis.

Autor: Rudwaleit M; Klinikum Bielefeld, Universitätsklinik für Innere Medizin und Rheumatologie, An der Rosenhöhe 27, 33647 Bielefeld, Germany., Machado PM; Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK.; Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, London, UK., Taieb V; UCB Pharma, Colombes, France., de Peyrecave N; UCB Pharma, Brussels, Belgium., Hoepken B; UCB Pharma, Monheim, Germany., Gensler LS; Department of Medicine/Rheumatology, University of California San Francisco, San Francisco, CA, USA.

Publikováno v: Therapeutic advances in musculoskeletal disease [Ther Adv Musculoskelet Dis] 2023 Aug 30; Vol. 15, pp. 1759720X231189079. Date of Electronic Publication: 2023 Aug 30 (Print Publication: 2023).

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání